Biotech Runners: MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), CytRx Corporation (NASDAQ:CYTR)
MannKind Corporation (NASDAQ:MNKD) had its price objective reduced by Cowen and Company from $5.50 to $5.00 in a report released on Wednesday,Stock Ratings News reports. Analysts at Piper Jaffray downgraded shares of MannKind Corporation (NASDAQ:MNKD) from a neutral rating to an underweight rating in a research note on Monday. MannKind Corporation (NASDAQ:MNKD) stock performance was…
